Regulatory News Service (RNS)

View all

Results, Reports and Presentations

• June 2025 Investor Presentation

  June 2 2025 Download (2.27MB)

• Indivior Q1 2025 Financial Results

  April 24 2025 Download (153KB)

• Annual Report and Accounts 2024

  March 17 2025 Download (7.25MB)

• Indivior FY and Q4 2024 Financial Results

  February 20 2025 Download (589KB)

• Indivior Announces Q3 2024 Financial Results

  October 24 2024 Download (334KB)

View all

Latest News

• Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

  June 19 2025

• Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

  June 2 2025

• Indivior Announces Patrick Barry as Chief Commercial Officer

  May 27 2025

• New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

  May 1 2025

• Indivior Announces Q1 2025 Financial Results

  April 24 2025

View all